Home/Pipeline/Novel Cancer Biomarkers (e.g., Autoantibodies)

Novel Cancer Biomarkers (e.g., Autoantibodies)

Various Cancers (Pancreatic, Ovarian)

Development & ValidationActive R&DN/A

Key Facts

Indication
Various Cancers (Pancreatic, Ovarian)
Phase
Development & Validation
Status
Active R&D
Company

About H.U. Group Holdings

H.U. Group Holdings is a mission-driven company focused on contributing to societal health through disease prevention, early diagnosis, and treatment support. It has achieved market dominance in Japan by strategically merging entities like SRL and Fujirebio to create a fully integrated model spanning biomarker research, reagent development, and nationwide testing services. Its strategy leverages this vertical integration for quality control, innovation speed, and recurring revenue, while expanding its international footprint in high-growth diagnostic segments like oncology and neurology.

View full company profile